Leuven, Belgium, ThromboGenics NV announces that the Company will be presenting a wide range of ophthalmic research at the upcoming EURETINA annual Congress held from September 8th – 11th 2016 in Copenhagen, Denmark.
EURETINA 2016 will see 15 communications delivering new scientific insights relevant to ThromboGenics development projects, by means of oral presentations, posters and instructional courses. Data will include preclinical and clinical research findings, as well as real-world clinical data, including further characterization of results from ocriplasmin studies such as OASIS and OVIID-I.
OASIS is the acronym for "Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion including Macular Hole". It is a Phase IIIB, randomized, prospective, sham-controlled, double-masked, multicenter clinical study. The goal of the study is to further evaluate the long-term (24 months) efficacy and safety of a single injection of 0.125mg of ocriplasmin in patients with symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT), including macular hole (MH). The full details of the OASIS results have now been published in Ophthalmology, the Journal of the American Academy of Ophthalmology (AAO), and will be presented at EURETINA by Prof Dr Pravin U. Dugel.*
As concluded by the AAO Journal, "the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additional safety signals identified".
Please click here for a complete overview of all presentations and poster delivered at the 16th Euretina Congress including date and time.
Dr Patrik De Haes, CEO of ThromboGenics nv, comments, "We are pleased to have the opportunity to share our cutting-edge research in the field of diabetic eye disease as well as continue to deliver a vast amount of ocriplasmin data in support of the retina community at this year's EURETINA Congress. The research insights will further grow confidence when considering ocriplasmin as a treatment option in a changing standard of care for the treatment of symptomatic VMA."